Expression Patterns of Glucose Transporter-1 Gene and Thyroid Specific Genes in Human Papillary Thyroid Carcinoma

Overview

Journal Nucl Med Mol Imaging

Publisher Springer

Date 2014 Jun 6

PMID 24900148

Citations 22

Authors

Sungeun Kim

June-Key Chung

Hae-Sook Min

Joo-Hyun Kang

Do Joon Park

Jae Min Jeong

Dong Soo Lee

Sung-Hwae Park

Bo Youn Cho

Sinae Lee

Myung Chul Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: The expression of glucose transporter-1 (Glut-1) gene and those of major thyroid-specific genes were examined in papillary carcinoma tissues, and the expressions of these genes were compared with cancer differentiation grades.

Materials And Methods: Twenty-four human papillary carcinoma tissues were included in this study. The expressions of Glut-1- and thyroid-specific genes [sodium/iodide symporter (NIS), thyroid peroxidase, thyroglobulin, TSH receptor and pendrin] were analyzed by RT-PCR. Expression levels were expressed as ratios versus the expression of beta-actin. Pathologic differentiation of papillary carcinoma was classified into a relatively well-differentiated group (n = 13) and relatively less differentiated group (n = 11).

Results: Glut-1 gene expression was significantly higher in the less differentiated group (0.66 ± 0.04) than in the well-differentiated group (0.59 ± 0.07). The expression levels of the NIS, PD and TG genes were significantly higher in the well-differentiated group (NIS: 0.67 ± 0.20, PD: 0.65 ± 0.21, TG: 0.74 ± 0.16) than in the less differentiated group (NIS: 0.36 ± 0.05, PD: 0.49 ± 0.08, TG: 0.60 ± 0.11), respectively. A significant negative correlation was found between Glut-1 and NIS expression, and positive correlations were found between NIS and TG, and between NIS and PD.

Conclusion: The NIS, PD and TG genes were highly expressed in well-differentiated thyroid carcinomas, whereas the Glut-1 gene was highly expressed in less differentiated thyroid carcinomas. These findings provide a molecular rationale for the management of papillary carcinoma, especially in the selection of FDG PET or radioiodine whole-body scan and I-131-based therapy.

Citing Articles

Computational Analysis Suggests That AsnGTT 3'-tRNA-Derived Fragments Are Potential Biomarkers in Papillary Thyroid Carcinoma.

Do A, Magesh S, Uzelac M, Chen T, Li W, Bouvet M Int J Mol Sci. 2024; 25(19).

PMID: 39408960 PMC: 11476591. DOI: 10.3390/ijms251910631.

An age-and sex-matched postoperative therapy should be required in thyroid papillary carcinoma.

Yan C, Sun J, He X, Jia L Front Endocrinol (Lausanne). 2024; 15:1339191.

PMID: 38974575 PMC: 11224517. DOI: 10.3389/fendo.2024.1339191.

Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.

Gimblet G, Whitt J, Houson H, Lin D, Guenter R, Rao T Surgery. 2023; 175(1):199-206.

PMID: 37919223 PMC: 11744986. DOI: 10.1016/j.surg.2023.05.045.

Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer.

Nagayama Y, Hamada K Metabolites. 2022; 12(12).

PMID: 36557253 PMC: 9782759. DOI: 10.3390/metabo12121214.

[F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.

de Koster E, van Engen-van Grunsven A, Bussink J, Frielink C, de Geus-Oei L, Kusters B Mol Imaging Biol. 2022; 25(3):483-494.

PMID: 36253663 PMC: 10172288. DOI: 10.1007/s11307-022-01776-4.

References

Chung J, So Y, Lee J, Choi C, Lim S, Lee D . Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med. 1999; 40(6):986-92. View

Ponte P, Ng S, Engel J, Gunning P, Kedes L . Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res. 1984; 12(3):1687-96. PMC: 318608. DOI: 10.1093/nar/12.3.1687. View

FEINE U, Lietzenmayer R, Hanke J, Held J, Wohrle H, Muller-Schauenburg W . Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996; 37(9):1468-72. View

Ward L, Santarosa P, Granja F, da Assumpcao L, Savoldi M, Goldman G . Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett. 2003; 200(1):85-91. DOI: 10.1016/s0304-3835(03)00392-6. View

Gerard A, Daumerie C, MESTDAGH C, Gohy S, de Burbure C, Costagliola S . Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab. 2003; 88(10):4977-83. DOI: 10.1210/jc.2003-030586. View

Albareda M, Puig-Domingo M, Wengrowicz S, Soldevila J, Matias-Guiu X, Caballero A . Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid. 1998; 8(5):385-91. DOI: 10.1089/thy.1998.8.385. View

Chung J, Kang J . Translational research using the sodium/iodide symporter in imaging and therapy. Eur J Nucl Med Mol Imaging. 2004; 31(6):799-802. DOI: 10.1007/s00259-004-1475-3. View

Chung J . Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002; 43(9):1188-200. View

Schonberger J, Ruschoff J, Grimm D, Marienhagen J, Rummele P, Meyringer R . Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid. 2002; 12(9):747-54. DOI: 10.1089/105072502760339307. View

10.

Nagayama Y, Kaufman K, Seto P, Rapoport B . Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun. 1989; 165(3):1184-90. DOI: 10.1016/0006-291x(89)92727-7. View

11.

Berho M, Suster S . The oncocytic variant of papillary carcinoma of the thyroid: a clinicopathologic study of 15 cases. Hum Pathol. 1997; 28(1):47-53. DOI: 10.1016/s0046-8177(97)90278-1. View

12.

Wang W, Macapinlac H, Larson S, Yeh S, Akhurst T, Finn R . [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999; 84(7):2291-302. DOI: 10.1210/jcem.84.7.5827. View

13.

Libert F, Ruel J, Ludgate M, Swillens S, Alexander N, Vassart G . Complete nucleotide sequence of the human thyroperoxidase-microsomal antigen cDNA. Nucleic Acids Res. 1987; 15(16):6735. PMC: 306137. DOI: 10.1093/nar/15.16.6735. View

14.

Robbins J, Merino M, Boice Jr J, Ron E, Ain K, Alexander H . Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med. 1991; 115(2):133-47. DOI: 10.7326/0003-4819-115-2-133. View

15.

Min J, Chung J, Lee Y, Jeong J, Lee D, Jang J . Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001; 28(5):639-45. View

16.

Lazar V, Bidart J, Caillou B, Mahe C, Lacroix L, Filetti S . Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab. 1999; 84(9):3228-34. DOI: 10.1210/jcem.84.9.5996. View

17.

Carrasco N . Iodide transport in the thyroid gland. Biochim Biophys Acta. 1993; 1154(1):65-82. DOI: 10.1016/0304-4157(93)90017-i. View

18.

Tanaka K, Otsuki T, Sonoo H, Yamamoto Y, Udagawa K, Kunisue H . Semi-quantitative comparison of the differentiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT-PCR. Eur J Endocrinol. 2000; 142(4):340-6. DOI: 10.1530/eje.0.1420340. View

19.

Grunwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J . Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid. 1997; 7(3):327-35. DOI: 10.1089/thy.1997.7.327. View

20.

Chung J, Lee Y, Kim C, Choi S, Kim M, Lee K . Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med. 1999; 40(2):339-46. View